Jing Cheong Asia Inc. dba New York Tong Ren Tang – FDA Warning Letter, Oct 1, 2026

On October 26, 2026, the U.S. Food and Drug Administration (FDA) issued a warning letter to Jing Cheong Asia Inc., doing business as New York Tong Ren Tang, following a September 2026 review of the company’s website. The FDA identified several products, including ‘Ofloxacin Eye Drops,’ ‘Jingzhi Niuhuang Jiedu Pian,’ and ‘Gui Pi Wan,’ as unapproved new drugs being sold in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). These products were marketed with therapeutic claims for treating serious conditions such as bacterial infections, heart disorders, and blood diseases without having the required FDA approval for safety and effectiveness. The Agency expressed particular concern regarding the eye drops, as ophthalmic products pose a higher risk by bypassing the body’s natural defenses. Additionally, the FDA flagged ‘Notoginseng Formula Special Gout Granule’ for potentially containing undeclared drug ingredients. To comply with the FD&C Act, the company must submit a written response within 15 business days outlining the corrective actions taken to address these violations and prevent their recurrence. Failure to resolve these issues may lead to legal actions, including product seizure or injunction.